Prostate cancer is a highly prevalent disease in older men of the Western world. Multiple complex molecular events characterize prostate cancer initiation, unregulated growth, invasion, and metastasis. While effective surgical and radiation treatments exist for clinically localized prostate cancer, metastatic disease remains essentially incurable and most men diagnosed with it will succumb over a period of months to years. Clinically, early detection of prostate cancer is guided by levels of prostate specific antigen (PSA). Importantly, PSA has very low specificity for the cancer and hence needle biopsy is routinely implemented for unequivocal detection of the disease. Needle biopsy in addition to being an invasive procedure, also has a propensity of missing the tumor. Thus there is an imminent need to develop additional biomarkers that can supplement PSA and increase its specificity for the disease. Although gene expression profiling and to some extent proteomic profiling has been explored as tools to nominate such biomarkers, assessment of metabolites for detection of cancer is still in its infancy. Notably, metabolites unlike genes or proteins are the outcome of biochemical processes and thus could be considered final denominators of tumor phenotype. Also, in addition to serving as potential biomarkers metabolomic profiles may provide additional information on altered pathways beyond that available from conventional transcriptomics and proteomics. Our laboratory has recently generated and analyzed a compendium of >600 metabolites across 42 prostate-derived tissues. Mining this compendium has resulted in metabolomic signatures for localized prostate cancer and advanced disease. Interestingly, among the metabolites included in the localized prostate cancer signature, sarcosine or N-methylglycine seems to have a functional role during prostate cancer development/progression. Importantly, sarcosine levels are significantly elevated in post-DRE urine sediments from biopsy verified prostate cancer patients compared to biopsy negative controls, making it an attractive biomarker candidate for non-invasive detection of the disease. This motivates the current proposal that aims to extend our preliminary observation with sarcosine to other metabolites in the tissue-specific localized prostate cancer signature. The overarching goal is to nominate and validate a panel of markers from this compendium that can assist in early and accurate detection of this deadly disease. Further in order to make this clinically relevant, we propose to use urine specimens from challenging cohort of patients who have high PSA level, wherein biopsy has to be used for confirmatory diagnosis. Our approach is to screen for levels of the target metabolites using a training set comprising of urine sediments from biopsy positive and negative individuals. The data will be used to nominate a subset of the metabolites that in combination present high accuracy in detecting the disease. This panel will then be validated in a blinded fashion on an independent set of clinical samples. To our knowledge this will be one of the first studies to develop a urine-based metabolomic assay for early detection of cancer. Given this the aims of the proposal are:
Specific Aim 1 : Metabololites associated with localized prostate cancer will be assessed in urine sediments from biopsy positive and negative individuals to nominate a metabolite signature that has diagnostic potential.
Specific Aim 2 : The """"""""Diagnostic Signature"""""""" will be validated in additional clinical samples

Public Health Relevance

Prostate cancer is the second largest cause of cancer-related death in US. The disease is often curable if detected early, while metastatic disease is often fatal. Given this, there is an imminent need to define additional biomarkers for prostate cancer detection owing to the low specificity of prostate specific antigen (PSA), the current clinical standard used for its early detection. The long term goal of this proposal is to define a subset of clinically relevant metabolomic markers in urine of prostate cancer patients that can be used for early and accurate diagnosis of the disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Research Grants (R03)
Project #
1R03CA139489-01
Application #
7657959
Study Section
Special Emphasis Panel (ZCA1-SRLB-F (J1))
Program Officer
Kagan, Jacob
Project Start
2009-07-15
Project End
2011-05-31
Budget Start
2009-07-15
Budget End
2010-05-31
Support Year
1
Fiscal Year
2009
Total Cost
$73,500
Indirect Cost
Name
Georgia Regents University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
966668691
City
Augusta
State
GA
Country
United States
Zip Code
30912
Khan, Amjad P; Rajendiran, Thekkelnaycke M; Ateeq, Bushra et al. (2013) The role of sarcosine metabolism in prostate cancer progression. Neoplasia 15:491-501
Poisson, Laila M; Sreekumar, Arun; Chinnaiyan, Arul M et al. (2012) Pathway-directed weighted testing procedures for the integrative analysis of gene expression and metabolomic data. Genomics 99:265-74
Richmond, Amy L; Kabi, Amrita; Homer, Craig R et al. (2012) The nucleotide synthesis enzyme CAD inhibits NOD2 antibacterial function in human intestinal epithelial cells. Gastroenterology 142:1483-92.e6
Choudhary, Vivek; Kaddour-Djebbar, Ismail; Lakshmikanthan, Vijayabaskar et al. (2011) Novel role of androgens in mitochondrial fission and apoptosis. Mol Cancer Res 9:1067-77
Putluri, Nagireddy; Shojaie, Ali; Vasu, Vihas T et al. (2011) Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. Cancer Res 71:7376-86
Putluri, Nagireddy; Shojaie, Ali; Vasu, Vihas T et al. (2011) Metabolomic profiling reveals a role for androgen in activating amino acid metabolism and methylation in prostate cancer cells. PLoS One 6:e21417
Vareed, Shaiju K; Bhat, Vadiraja B; Thompson, Christopher et al. (2011) Metabolites of purine nucleoside phosphorylase (NP) in serum have the potential to delineate pancreatic adenocarcinoma. PLoS One 6:e17177
Khan, Amjad P; Poisson, Laila M; Bhat, Vadiraja B et al. (2010) Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer. Mol Cell Proteomics 9:298-312